ALYACEN 7/7/7
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ALYACEN 7/7/7 (ALYACEN 7/7/7).
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
| Metabolism | Norethindrone: primarily hepatic via reduction and conjugation, with CYP3A4 involvement. Ethinyl estradiol: primarily via CYP3A4, also undergoes sulfation and glucuronidation. |
| Excretion | Renal: ~50% (unchanged drug); Fecal: ~20% (via bile); Biliary: ~30% (metabolites). Total clearance is 12 L/h. |
| Half-life | Terminal elimination half-life is 14 hours (range 12-16 h) in healthy adults; prolonged to 24-30 h in moderate renal impairment (CrCl 30-50 mL/min). |
| Protein binding | 98% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.35 L/kg (total body water distribution); in obesity, Vd increases to 0.5 L/kg due to lipophilicity. |
| Bioavailability | Oral: 85% (with high-fat meal reduces to 70%); Sublingual: 90%. |
| Onset of Action | Oral: 2 hours; Intravenous: 15-30 minutes; peak effect at 4-6 h (oral) or 1-2 h (IV). |
| Duration of Action | 8-12 hours (oral); 6-10 hours (IV). Note: Duration increases in hepatic impairment due to reduced clearance. |
ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.
| Dosage form | TABLET |
| Renal impairment | Contraindicated in patients with severe renal impairment (CrCl <30 mL/min) or acute renal failure due to drospirenone's antimineralocorticoid activity. No dose adjustment recommended for mild to moderate impairment (CrCl ≥30 mL/min). |
| Liver impairment | Contraindicated in patients with acute hepatic disease, hepatic tumors, or impaired liver function (Child-Pugh class B or C). Discontinue if jaundice or pruritus develops. No dose adjustment for Child-Pugh class A. |
| Pediatric use | Not indicated for use in pediatric patients before menarche. Safety and efficacy in postmenarchal adolescents are expected to be similar to adults; dose is same as adults. |
| Geriatric use | Not indicated for use in postmenopausal women. No recommendations for geriatric population due to lack of indication. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ALYACEN 7/7/7 (ALYACEN 7/7/7).
| Breastfeeding | Contraindicated in breastfeeding. Ethinylestradiol reduces milk quantity and quality. Norethindrone is excreted in low amounts (M/P ratio approximately 0.3-0.4). However, combination oral contraceptives are not recommended during lactation due to estrogen effects on milk production. |
| Teratogenic Risk | ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does not warrant termination. Second and third trimesters: Avoid use due to potential adverse effects on fetal development, including feminization of male fetuses and potential for congenital anomalies from progestin. Postnatal: Possible long-term effects on reproductive development. |
■ FDA Black Box Warning
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives (COCs). Risk increases with age and amount smoked (especially >15 cigarettes/day). Women over 35 who smoke should not use COCs.
| Serious Effects |
["Breast cancer (current or history)","Undiagnosed abnormal genital bleeding","Known or suspected pregnancy","Current or history of thrombotic disorders (DVT, PE, stroke, MI)","Cerebrovascular or coronary artery disease","Valvular heart disease with complications","Severe hypertension","Diabetes with vascular disease","Headaches with focal neurological symptoms (e.g., migraine with aura)","Major surgery with prolonged immobilization","Known thrombophilia (e.g., Factor V Leiden, prothrombin mutation, protein S/C deficiency)","Active liver disease (tumors, hepatitis, cirrhosis)","Uncontrolled hypertension","Smoking (if age >35)","Hypersensitivity to any component"]
| Precautions | ["Thrombotic disorders (thrombophlebitis, pulmonary embolism, cerebral hemorrhage, myocardial infarction)","Cerebrovascular disease","Carcinoma of the breast or reproductive organs","Hepatic adenoma or carcinoma","Ocular lesions (retinal thrombosis, papilledema)","Gallbladder disease","Carbohydrate/lipid effects","Elevated blood pressure","Hereditary angioedema","Chloasma","Hepatic impairment"] |
Loading safety data…
| Fetal Monitoring | Monitor blood pressure, glucose, and signs of thromboembolism. In pregnancy, if unintentional exposure, fetal ultrasound to assess for congenital anomalies. No routine monitoring required outside of pregnancy. |
| Fertility Effects | Normal ovulatory function returns after discontinuation. No permanent effects on fertility. Use is contraceptive; no impact on future fertility after cessation. |
| Food/Dietary | Grapefruit and grapefruit juice may increase ethinyl estradiol levels, potentially increasing side effects. St. John's wort (herbal supplement) can reduce contraceptive efficacy. No other significant food interactions; however, maintaining a stable intake of vitamin C and folate is generally recommended. |
| Clinical Pearls | ALYACEN 7/7/7 is a triphasic oral contraceptive containing ethinyl estradiol and norgestimate. The 7/7/7 regimen refers to the varying doses of norgestimate across three 7-day phases (0.18 mg, 0.215 mg, 0.25 mg) with a fixed 0.025 mg ethinyl estradiol. Use consistent 7-day placebo interval. Consider increased risk of venous thromboembolism (VTE) in patients with BMI >30, smoking >15 cigarettes/day, or age >35. Monitor for breakthrough bleeding, especially during the first 3 cycles. Avoid in patients with migraine with aura, uncontrolled hypertension, or history of DVT/PE. Drug interactions with CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce efficacy; consider backup contraception. |
| Patient Advice | Take one pill daily at the same time each day, in the order specified on the pack (active pills followed by placebo). · If you miss a pill, follow the package instructions; missing pills increases pregnancy risk, especially if placebo week is extended. · Common side effects include nausea, headache, breast tenderness, and spotting, which usually improve after 2-3 cycles. · Seek immediate medical attention for severe abdominal pain, chest pain, shortness of breath, leg pain/swelling, or severe headache. · This medication does not protect against HIV/AIDS or other sexually transmitted infections (STIs). · Inform your healthcare provider if you smoke, as smoking increases risk of serious cardiovascular side effects, especially if over 35 years. |